1. Home
  2. BWA vs EXEL Comparison

BWA vs EXEL Comparison

Compare BWA & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BorgWarner Inc.

BWA

BorgWarner Inc.

HOLD

Current Price

$63.05

Market Cap

10.5B

ML Signal

HOLD

Logo Exelixis Inc.

EXEL

Exelixis Inc.

HOLD

Current Price

$43.87

Market Cap

11.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWA
EXEL
Founded
1987
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5B
11.1B
IPO Year
1993
2000

Fundamental Metrics

Financial Performance
Metric
BWA
EXEL
Price
$63.05
$43.87
Analyst Decision
Buy
Buy
Analyst Count
15
21
Target Price
$55.73
$46.60
AVG Volume (30 Days)
3.4M
2.6M
Earning Date
02-11-2026
02-10-2026
Dividend Yield
1.08%
N/A
EPS Growth
N/A
57.95
EPS
1.28
2.78
Revenue
$14,316,000,000.00
$2,320,126,000.00
Revenue This Year
$3.68
$14.86
Revenue Next Year
$2.55
$14.93
P/E Ratio
$49.06
$15.80
Revenue Growth
1.63
6.98
52 Week Low
$24.40
$32.38
52 Week High
$70.08
$49.62

Technical Indicators

Market Signals
Indicator
BWA
EXEL
Relative Strength Index (RSI) 82.25 51.45
Support Level $47.02 $40.92
Resistance Level $70.08 $44.28
Average True Range (ATR) 2.37 1.48
MACD 1.82 0.03
Stochastic Oscillator 77.10 70.53

Price Performance

Historical Comparison
BWA
EXEL

About BWA BorgWarner Inc.

BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: